Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
5.72
+0.12 (2.14%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Akari Therapeutics, Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 9.28 | 9.66 | 11.36 | 13.53 | 8.08 | |
| Research & Development | 2.82 | 6.98 | 5.45 | 9.56 | 9.13 | |
| Operating Expenses | 12.1 | 16.65 | 16.81 | 23.09 | 17.21 | |
| Operating Income | -12.1 | -16.65 | -16.81 | -23.09 | -17.21 | |
| Interest Expense | -0.95 | -0.24 | - | - | - | |
| Interest & Investment Income | 0 | 0.01 | 0.08 | 0.05 | 0.01 | |
| Currency Exchange Gain (Loss) | -0.44 | 0.01 | 0.14 | 0.45 | -0.19 | |
| Other Non Operating Income (Expenses) | 3.53 | 2.08 | 6.58 | 4.84 | -0.03 | |
| EBT Excluding Unusual Items | -9.96 | -14.8 | -10.01 | -17.75 | -17.42 | |
| Merger & Restructuring Charges | - | -5 | - | - | - | |
| Asset Writedown | -5.18 | - | - | - | - | |
| Other Unusual Items | -3.16 | - | - | - | - | |
| Pretax Income | -18.3 | -19.79 | -10.01 | -17.75 | -17.42 | |
| Income Tax Expense | -1 | - | - | - | - | |
| Net Income | -17.3 | -19.79 | -10.01 | -17.75 | -17.42 | |
| Net Income to Common | -17.3 | -19.79 | -10.01 | -17.75 | -17.42 | |
| Shares Outstanding (Basic) | 1 | 0 | 0 | 0 | 0 | |
| Shares Outstanding (Diluted) | 1 | 0 | 0 | 0 | 0 | |
| Shares Change (YoY) | 181.85% | 144.03% | 56.79% | 45.46% | 35.87% | |
| EPS (Basic) | -20.55 | -66.28 | -81.79 | -227.41 | -324.77 | |
| EPS (Diluted) | -20.55 | -66.28 | -81.79 | -227.41 | -324.77 | |
| Free Cash Flow | -10.57 | -12.55 | -16.43 | -21.5 | -18.85 | |
| Free Cash Flow Per Share | -12.56 | -42.04 | -134.29 | -275.54 | -351.28 | |
| EBITDA | -12.08 | -16.63 | -16.8 | -23.08 | -17.21 | |
| D&A For EBITDA | 0.01 | 0.01 | 0 | 0 | 0 | |
| EBIT | -12.1 | -16.65 | -16.81 | -23.09 | -17.21 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.